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Summary: α,-Acid glycoprotein, an acute phase reactant synthesised by the liver, has been reported to be
increased in neoplastic conditions and reduced in chronic liver disease. We measured serum aracid glycoprotein
by a nephelometric method in 186 subjects (112 males, 74 females): 55 had mild chronic liver disease (chronic
hepatitis and steatofibrosis), 45 cirrhosis, 38 hepatocellular carcinoma, 15 extra-hepatic malignant disease; 33
healthy subjects were used as controls. Analysis of variance demonstrated a significant variability among
groups (F = 17.08, P = 0.0000). Higher concentrations of ocj-acid glycoprotein were detected in malignant
extra-hepatic disease than in all other groups (P < 0.01); concentrations of o^-acid glycoprotein were higher
in hepatocellular carcinoma than in cirrhosis (P < 0.01). Multiple regression analysis by groups (dependent
variable = αϊ-acid glycoprotein; group 1 = mild chronic liver disease + cirrhosis; group 2 = hepatocellular
carcinoma) showed a significant correlation for both group 1 (r = 0.6264, F = 8.005, P = 0.0000) and group 2
(r = 0.8947, F = 13.643, P = 0.0000). The significant standardised regression coefficients were: cholinesterase,
C-reactive protein, γ-glutamyltransferase and iron (negative) for regression upon group 1; C-reactive protein,
aj-antiproteinase, γ-glutamyltransferase, iron (negative) for regression upon group 2. A difference between
the 2 regression equation coefficients was detected (F = 5.209, P = 0.0002). In conclusion, a raised aracid
glycoprotein concentration was found in patients with malignancies, both hepatic and extra-hepatic; however,
patients with hepatocellular carcinoma had a lower aj-acid glycoprotein concentration than patients with
malignant extra-hepatic disease. In hepatocellular carcinoma, a good correlation existed between aracid
glycoprotein and other serum indices of the acute phase response. In some patients with hepatocellular
carcinoma, at-acid glycoprotein was increased, despite the decrease of liver function.
Introduction
at-Acid glycoprotein is a circulating glycoprotein syn-
thesized mainly in the liver. It has a relative molecular
mass of about 41000 and is characterized by the
presence of five glycosylation sites (1, 2). arAcid
glycoprotein has long been recognized as an acute
phase reactant (3). Thus, its concentration increases
2—10 fold in serum, under conditions that promote
the increase of other acute phase proteins such as ar
antiproteinase and C-reactive protein; moreover, its
synthesis in human adult hepatocytes is augmented
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by interleukin-1 and interleukin-6, cytokines that are
considered the main mediators of the acute phase
response (4).
Previous studies have shown that the at-acid glyco-
protein concentration rises in serum during the course
of several neoplastic diseases (5 — 7), including hepa-
tocellular carcinoma in Asian patients (8).
However, hepatocellular carcinoma has a striking ge-
ographical variation and in industrialised countries,
where its incidence is relatively low, hepatocellular
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carcinoma develops almost always in patients with
long-standing cirrhosis. In contrast, in high incidence
areas (e. g. Far-East Asia) hepatocellular carcinoma
is common even in the absence of cirrhosis (9). Unlike
other acute phase reactants (like arantiproteinase),
aracid glycoprotein does not increase in advanced
chronic liver disease and may be actually markedly
decreased in such conditions (10 — 13). In this context,
the question arises as to whether the variations of ar
acid glycoprotein concentration in the acute phase
response to neoplasia is influenced by the decline of
the hepatic synthetic function, which accompanies the
development of hepatocellular carcinoma in a cir-
rhotic liver. The aim of the present study was to
ascertain the existence or otherwise of such a patho-
physiological interaction.
Materials and Methods
Pat ients
We studied a total of 186 subjects (112 male and 74 female,
mean age 54.5 ± 14.2 years), divided in 5 categories according
to their diagnosis; their characteristics are listed in table 1. The
following criteria used for the definition of the categories.
Mild chronic liver disease was defined, on the histological
evidence of percutaneous liver biopsy, as a) chronic persistent
hepatitis, b) chronic active hepatitis, or c) steatofibrosis.
Cirrhosis was diagnosed on the basis of clinical evidence (hy-
poalbuminaemia, hypergammaglobulinaemia, ascites, oesopha-
geal varices) and/or histological evidence of cirrhosis; devel-
opment of primary liver cancer in patients belonging to this
group was excluded on the basis of negative results of diagnostic
imaging and biohumoral (ocrfetoprotein) tests.
Conversely, hepatocellular carcinoma, which in our patients
always developed in the setting of long-standing liver cirrhosis,
was always confirmed histologically or at autopsy.
Malignant disease of extra-hepatic origin was also diagnosed
histologically or at autopsy; more precisely, this group con-
tained 5 patients with pancreatic carcinoma, 5 with gastric
carcinoma, 1 with oesophageal carcinoma, 1 with ovarian can-
cer, 1 with lung cancer, 1 with high-grade non-Hodgkin lym-
phoma, 1 with malignant pheochromocytoma. Eight of these
patients had evidence of hepatic metast ses at the time serum
was collected for the present study.
Healthy blood donors were used as a control group.
Biochemical de terminat ions
Sera were immediately stored at -20 °C after collection and
kept frozen until use. At the time the determination of a,-acid
glycoprotein was performed, sera h$d been stored for a maxi-
mum of 12 months. arAcid glycoprotein was determined si-
multaneously in all sera with a nephelometric method (BNA,
Behring, Germany). Intra-assay and inter-assay coefficients of
variations were 2.0% and 3.5%, respectively.
All other determinations were performed with standard com-
mercial kits.
Statistical analysis
One-way analysis of variance was applied to detect differences
in the population means with regard to aracid glycoprotein
concentrations. BonferronCs test was used for multiple com-
parisons among the groups. One-way analysis of covariance
was used to exclude the possibility that variations of renal
function (measured by serum creatinine) might exert a decisive
influence on ocracid glycoprotein concentration. The Pearson
X2-test was used to test the existence of differences among the
groups with regard to categorized variables (such as normal or
pathological αϊ-acid glycoprotein concentration). Multiple re-
gression analysis was utilized to investigate the correlation of
serum aracid glycoprotein variations with variations of several
other biohumoral conditions. The analysis was performed on
the patients as a single group, as well as on 2 subgroups (first
subgroup: chronic liver disease H- cirrhosis; second subgroup:
hepatocellular carcinoma). In order to detect differences in the
slopes or the intercepts between the regressions of the subroups,
analysis of variance of the regression coefficients was per-
formed. In view of their scattered distribution, the results of
oci-acid glycoprotein and C-reactive protein determinations were
transformed logarithmically when appropriate. All statistical
tests were performed with the BMDP™ statistical software
package (14).
Results
Figure 1 presents the individual values of serum ocr
acid glycoprotein measured in the various groups of
patients. Using a cut-off value of 1 g/1, we detected a
significant difference between the observed and the
expected frequency of pathological αϊ-acid glycopro-
tein values (Pearson x24est 65.93, Ρ = 0.0000). α,-
Acid glycoprotein was higher in patients with malig-
nancies (both hepatic and extra-hepatic). One-way
analysis of variance demonstrated the existence of a
significant difference among groups (F = 17.08,
Ρ = 0.0000). Patients with malignant extra-hepatic
Tab. 1. Characteristics of the studied population.
Healthy controls
Chronic liver disease
Liver cirrhosis
Hepatocellular carcinoma
Extra-hepatic malignancies
Ν
33
55
45
38
15
Sex
c?
15
31
22
34
10
$
18
24
23
04
05
Age
(a, x ± SD)
41.8 ± 14.7
51.0 + 13.1 '
58.3 ± 11.0*
62.6 +11.6
62.8 ± 08.1
Age range
(a)
20-68
21-73
36-76
33-80
43-77
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Fig. 1. Individual values of aracid glycoprotein grouped according to diagnosis. The doited line represents the upper reference
limit (1 g/1).
Tab. 2. Multiple regression analysis. The analysis was performed using aracid glycoprotein as the dependent variable and
cholinesterase, C-reactive protein, ocj-antiproteinase, γ-glutamyltransferase and iron as predictor variables. The regression
analysis was performed on the total collective, as well as on separate groups.
Regression Multiple r Multiple r2
All patients
Chronic non-neoplastic liver disease
Hepatocellular carcinoma
0.6140
0.6264
0.8947
0.3770
0.3923
0.8005
10.287
8.005
13.643
0.0000
0.0000
0.0000
disease had higher ovacid glycoprotein concentra-
tions than all other groups (P < 0.01); patients with
hepatocellular carcinoma had higher concentrations
than cirrhotics (P < 0.01) (Bonferronfs test for pair-
wise comparisons). Table 2 shows the results of the
multiple regression analysis, taking serum o^-acid gly-
coprotein as the dependent variable, and C-reactive
protein, oci-antiproteinase, cholinesterase,1) γ-
glutamyltransferase1) and iron serum concentrations
as predictor variables. The analysis was performed
for the subjects as a single collective, as well as by
groups. In the analysis of the single collective, the
standardized regression coefficients of all predictor
variables were found to be significant: oci-antiprotei-
nase (T = 3.48, P = 0.00), C-reactive protein
(T = 3.60, P = 0.00), cholinesterase (T = 4.20,
P = 0.00), γ-glutamyltransferase (T = 2.07,
!) Cholinesterase (EC 3.1.1.8)
γ-Glutamyl transpeptidase (EC 2.3.2.2)
Sialyltransferase (EC 2.4.99.6)
P = 0.04) and iron (T = -2.93, P = 0.00). In the
analysis of results from patients with chronic, non-
neoplastic liver disease, significant standardized re-
gression coefficients were found for iron (T = —3.12,
ρ = 0.00), C-reactive protein (T = 2.51, P = 0.01),
γ-glutamyltransferase (T = 2.22, P = 0.03) and cho-
linesterase (T = 3.26, P = 0.00). In the analysis of
results from patients with hepatocellular carcinoma,
significant standardized regression coefficients were
found for arantiproteinase (T = 7.54, P = 0.00), C-
reactive protein (T = 4.01, P = 0.00), γ-glutamyl-
transferase (T = 2.12, P = 0.05) and iron
(T = -2.75, P = 0.01). The analysis of variance of
regression coefficients over groups was also statisti-
cally significant (F = 5.209, P = 0.0002). Finally, se-
rum creatinine displayed a significant correlation with
ocracid glycoprotein (r = 0.170, P = 0.024). How-
ever, analysis of covariance enabled us to prove that
a significant variability among groups with regard to
oct-acid glycoprotein concentration still existed after
adjustment for creatinine (F = 13.16, P = 0.000).
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Discussion
In the present study, the great majority of ourpatients
with extra-hepatic malignant disease (86.7% of this
group) had an αϊ-acid glycoprotein concentration
above a cut-off value of 1 g/1 (representing mean
+ 2 SD of our control subjects). Moreover, this group
of patients exhibited the highest aracid glycoprotein
values. In contrast, only 34.2% of patients with he-
patocellular carcinoma showed a,-acid glycoprotein
concentrations above the cut-off. Although oci-acid
glycoprotein was significantly increased in hepatocel-
lular carcinoma in comparison to cirrhosis, it was also
significantly lower in comparison with other neoplas-
tic diseases. Patients with chronic, non-malignant liver
disease did not differ from controls with respect to
αϊ-acid glycoprotein.
Serum concentrations of glycoproteins can be influ-
enced by the mass of functional liver in various ways.
Firstly, an impairment of hepatic synthetic ability
might lead to a decrease of their production, since
they are mostly synthesized by the liver. In effect, our
data indicate that the aracid glycoprotein concentra-
tions of patients with chronic, non-neoplastic disease
of the liver show a positive correlation with cholin-
esterase, one of the more reliable indices of liver
synthetic function. However, the liver is also the main
site of glycoprotein catabolism, which depends on
uptake through specific surface receptors which rec-
ognize asialoforms of circulating glycoproteins (15).
a,-Acid glycoprotein appears to have a higher clear-
ance rate than other glycoproteins expressed during
the acute phase response, like ceruloplasmin and hap-
toglobin (16). Therefore, serum aracid glycoprotein
concentration might increase because less is taken up
by the reduced hepatic mass (17). We found similar
aracid glycoprotein concentrations among patients
with chronic non-neoplastic liver disease and control
subjects. A possible explanation of this finding might
be the existence in the organism of a balance that is
maintained between reduced synthesis and impaired
catabolism of this glycoprotein. However, in the pres-
ence of an acute phase response, as in neoplastic
conditions, a raised proportion of glycoprotein sialo-
forms (not recognized by liver cell receptors which
are able to recognize only asialoforms, as noted
above) appears in the serum (18,19). Thus, one might
speculate that the equilibrium that seems to exist in
chronic, non-neoplastic liver disease could be dis-
rupted by the appearance of an increased proportion
of sialo-forms of ai-acid glycoprotein, possibly related
to increased sialyltransferase1) activity (13, 19—23).
In accordance with this hypothesis, aracid glycopro-
tein showed a strong correlation with other acute
phase indices (arantiproteinase, C-reactive protein
and iron) in the group of patients with hepatocellular
carcinoma.
Our data are only in partial agreement with previous
reports (8). The incidence of pathologically elevated
oci-acid glycoprotein concentrations was not as high
as that previously described in hepatocellular carci-
noma in Asian patients. Geographical variations in
the clinical presentation of hepatocellular carcinoma
might explain this discrepancy, since our patients were
all Italian and developed primary liver cancer always
in the setting of long-standing cirrhosis. A correct
interpretation of these results in relation to earlier
conflicting studies is limited by the fact that we could
not test sera of patients with hepatocellular carcinoma
of different geographical origin. The existence of these
differences may, however, represent indirect confir-
mation of the hypothesis that the decline of liver
synthetic function limits the rise of aj-acid glycopro-
tein serum concentration in patients with the type of
hepatocellular carcinoma commonly encountered in
our country.
In conclusion, aracid glycoprotein was found to be
elevated in hepatocellular carcinoma, but it was not
as high as in patients with extra-hepatic tumours. A
good correlation existed between aracid glycoprotein
and other serum indices of the acute phase response;
in this setting, it appears that at-acid glycoprotein is
able to increase despite a decline of liver function.
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